A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes
Authors:
- A. G. VakrakouAVA. G. Vakrakou
- D. TzanetakosDTD. Tzanetakos
- S. ValsamiSVS. Valsami
- E. GrigoriouEGE. Grigoriou
- K. PsarraKPK. Psarra
- J. TzartosJTJ. Tzartos
- M. AnagnostouliMAM. Anagnostouli
- E. AndreadouEAE. Andreadou
- M. E. EvangelopoulosM. E. Evangelopoulos
- G. KoutsisGKG. Koutsis
- C. ChrysovitsanouCCC. Chrysovitsanou
- E. GialafosEGE. Gialafos
Open Access
- 29 October 2018
- journal article
- case report
- Published by Springer Nature in BMC Neurology
- Vol. 18 (1) , 178
Abstract
Alemtuzumab has been demonstrated to reduce the risks of relapse and accumulation of sustained disability in Multiple Sclerosis (MS) patients compared to β-interferon. It acts against CD52, leading primarily to lymphopenia. Recent data have shown that mild neutropenia is observed in 16% of treated MS-patients whereas severe neutropenia occurred in 0.6%. Herein, we present the case of a 34-year-old woman with relapsing-remitting MS, with a history of treatment with glatiramer acetate and natalizumab, who subsequently received Alemtuzumab (12 mg / 24 h × 5 days). 70-days after the last Alemtuzumab administration, the patient displayed neutropenia (500 neutrophils/μL) with virtual absence of B-cells (0.6% of total lymphocytes), low values of CD4-T-cells (6.6%) and predominance of CD8-T-cells (48%) and NK-cells (47%); while large granular lymphocytes (LGL) predominated in the blood-smear examination. Due to prolonged neutropenia (5-days) the patient was placed on low-dose corticosteroids leading to sustained remission. This is the first case of a patient with relapsing-remitting MS with neutropenia two months post-Alemtuzumab, with simultaneous presence of LGL cells in the blood and a robust therapeutic response to prednisolone. We recommend testing with a complete blood count every 15 days in the first 3 months after the 1st Alemtuzumab administration and searching for large granular lymphocytes cell expansion on microscopic examination of the peripheral blood if neutropenia develops.Keywords
This publication has 17 references indexed in Scilit:
- Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohortMultiple Sclerosis Journal, 2016
- Alemtuzumab in Multiple Sclerosis: Mechanism of Action and BeyondInternational Journal of Molecular Sciences, 2015
- Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?2014
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialThe Lancet, 2012
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialThe Lancet, 2012
- Pathophysiologic mechanisms and management of neutropenia associated with large granular lymphocytic leukemiaExpert Review of Hematology, 2011
- Neutropenia associated with rituximab therapyCurrent Opinion in Hematology, 2011
- Late-Onset Neutropenia After Rituximab TreatmentMedicine, 2010
- Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumabBlood, 2009
- T-Cell Large Granular Leukemia and Related ProliferationsAmerican Journal of Clinical Pathology, 2007